| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. | Vaccine | 2006 | 1.16 |
| 2 | Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. | Cancer Res | 2004 | 0.96 |
| 3 | Yeasts encoding tumour antigens in cancer immunotherapy. | Expert Opin Biol Ther | 2005 | 0.95 |
| 4 | Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. | Mol Ther | 2012 | 0.85 |
| 5 | Regulation of Fas-mediated apoptosis by N-ras in melanoma. | J Invest Dermatol | 2002 | 0.84 |
| 6 | Enhancing antimelanoma immune responses through apoptosis. | Cancer Gene Ther | 2003 | 0.83 |